BNT162b2 COVID-19 Vaccine has no Adverse Effect on Women’s In Vitro Fertilization Outcomes and Fertility

Abstract

Purpose: To investigate the effect of BNT162b2 COVID-19 vaccine on women’s fertility. Methods: We prospectively collected data of women patients undergoing In Vitro Fertilization (IVF) treatment after completion of 2 doses of BNT162b2 vaccination between February and April 2021 (POST vaccine). For comparison, we reviewed records of the same patients before the vaccination (PRE vaccine) up to February 2019. Each woman served as self-control before and after vaccination. Study outcomes were compared between the PRE- and POSTvaccination groups. Clinical pregnancy values were assessed if data were available for both cycles. Results: 47 women were eligible, with a mean interval of 362 ± 368 days between the two ovum pick-ups. The numbers of oocytes retrieved, matured oocytes, fertilization rates, and numbers and qualities of embryos at day 3 before-and-after vaccinations were similar for all parameters. The numbers and percentages of clinical pregnancies did not differ significantly between the two vaccination groups. Conclusion: From our findings, the vaccine does not affect women’s in vitro outcomes and, therefore, fertility. This study repudiates misinformation from unreliable sources, reassuring patients to improve compliance and promote COVID-19 eradication.